Cvs (CVS) Stock
Retail pharmacy giant with insurance and care services. Here's the price, business snapshot, and what's worth knowing about Cvs in June 2026.
CVS Health Corporation is a large integrated healthcare company combining retail pharmacies, pharmacy benefit management (Caremark), and a health insurance arm following its acquisition of Aetna. With a market capitalisation around $105.3bn, CVS aims to offer end-to-end care solutions — from prescriptions and in-store clinical services (MinuteClinic) to care management and insurance products. Investors should note the company’s diversified revenue streams and potential cost synergies from vertical integration, but also be aware of material regulatory, reimbursement and competitive risks. Profitability depends on drug pricing dynamics, insurance margins, and effective cost control across vast retail and clinical operations. The business carries a significant debt load from past acquisitions, so interest-rate sensitivity and cash generation matter. CVS has historically returned cash to shareholders and can be of interest to income and value-oriented investors, though performance can vary and this is general information, not investment advice.
Why It’s Moving
CVS is drawing fresh analyst support as investors look past short-term noise and toward a steadier 2026 earnings recovery.
- Analysts have stayed upbeat on CVS, with multiple forecast trackers showing a Buy or Strong Buy consensus and double-digit implied upside, suggesting Wall Street sees room for the recovery to continue.
- The latest earnings narrative has centered on better-than-expected profitability and improved full-year guidance, which matters because it signals CVS may be stabilizing after a period of healthcare-benefit pressure.
- Investor focus remains on the company’s long-term earnings power, especially whether pharmacy and benefits trends can support the projected rebound that underpins the bullish 2026 outlook.
CVS is drawing fresh analyst support as investors look past short-term noise and toward a steadier 2026 earnings recovery.
- Analysts have stayed upbeat on CVS, with multiple forecast trackers showing a Buy or Strong Buy consensus and double-digit implied upside, suggesting Wall Street sees room for the recovery to continue.
- The latest earnings narrative has centered on better-than-expected profitability and improved full-year guidance, which matters because it signals CVS may be stabilizing after a period of healthcare-benefit pressure.
- Investor focus remains on the company’s long-term earnings power, especially whether pharmacy and benefits trends can support the projected rebound that underpins the bullish 2026 outlook.
When is the next earnings date for CVS (CVS)?
CVS Health’s next earnings release is expected around July 30, 2026, based on its usual late-July reporting pattern, though the company has not formally confirmed the date. The report will cover Q2 2026 results. For investor briefing purposes, this is the next scheduled update on operating performance and guidance after the Q1 2026 report.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying CVS stock with a target price of $63.79, indicating strong growth potential.
Financial Health
CVS is maintaining strong revenue and cash flow, but its profitability margins are relatively low.
Dividend
CVS's dividend yield of 2.61% is reasonable for investors seeking income. If you invested $1000 you would be paid $26.10 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
CHEMED CORP
Provides hospice and palliative care services to patients facing life-limiting illness
ALIGNMENT HEALTHCARE INC
Alignment Healthcare, Inc. is a consumer-centric platform designed to improve the healthcare experience for seniors. The Company’s operations primarily consist of Medicare Advantage Plans in the states of California, North Carolina, Nevada, Arizona, Florida and Texas. It partners with local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology (AVA). AVA’s capabilities include consumer experience, internal care delivery, external providers, health plan operations and growth operations. AVA offers a digital ecosystem that enables its members and their support system to get the information and care they need, when and how they need it. With their AVA-powered member portal and mobile app, seniors have many self-service capabilities and can get 24/7 care, send secure messages to their concierge and care teams, check their rewards and ACCESS On-Demand Concierge Card balance, and view their health history.
Brookdale
A leading owner and operator of senior living communities in the United States.
Baskets Featuring CVS
The GLP-1 Insurance Gap Reshaping Weight Care in 2026
Cigna's decision to drop coverage for popular GLP-1 weight-loss drugs like Wegovy and Zepbound for its employees signals a potential shift in employer-sponsored healthcare. This policy change could drive significant demand toward affordable direct-to-consumer telehealth platforms and alternative digital weight management programs.
Published: 3 June 2026
Explore BasketMedicare Advantage Rate Hike Opportunities in 2026
The Centers for Medicare & Medicaid Services finalized a 2.48% payment increase for 2027, granting health insurers a surprise $13 billion funding boost. This collection features managed care organizations and healthcare providers poised to benefit from this highly favorable regulatory reversal.
Published: 10 April 2026
Explore BasketRegulatory Relief Stocks | FTC Court Ruling Impact
A federal appeals court has overturned an FTC order against Intuit, significantly limiting the agency's ability to use internal judges. This precedent forces regulators to face higher burdens of proof in federal court, providing potential relief to corporations fighting administrative overreach.
Published: 21 March 2026
Explore BasketDefensive Equities | Risks in a Slowing Labour Market
After the U.S. economy unexpectedly shed 92,000 jobs in February, investors are seeking shelter from the resulting market volatility. This collection features resilient, non-cyclical companies that historically maintain their value and offer stability during periods of economic deceleration.
Published: 9 March 2026
Explore BasketUS Jobs Surge | Healthcare & Construction Stocks
The U.S. labor market showed surprising strength in January, adding far more jobs than anticipated, led by the healthcare and construction industries. This theme focuses on the companies benefiting from this robust and targeted hiring, signaling a potential expansion in these key sectors.
Published: 12 February 2026
Explore BasketSafety Stocks: Might Fed Volatility Boost Demand?
An unprecedented criminal probe into the Federal Reserve Chair threatens the central bank's independence and injects political uncertainty into monetary policy. This environment could create a flight to safety, benefiting companies that are resilient during times of market volatility.
Published: 12 January 2026
Explore BasketMedicare Cost Stocks (UNH, CVS) May Benefit
The U.S. government's successful negotiation of lower prices for key Medicare drugs signals a major shift in pharmaceutical pricing power. This creates a potential investment opportunity in managed care and healthcare service companies poised to benefit from the system's increased focus on cost efficiency.
Published: 26 November 2025
Explore BasketDow 48,000 Rally: Bull Market Risks & Opportunities
The Dow Jones Industrial Average has surpassed 48,000 for the first time, driven by strong performance in the healthcare and financial sectors. This milestone suggests a bullish outlook on the U.S. economy, creating opportunities among the leading blue-chip companies.
Published: 14 November 2025
Explore BasketObesity Drug Pricing | Pharma Investment Theme
New agreements with Eli Lilly and Novo Nordisk are set to dramatically lower the cost of popular weight-loss drugs, making them accessible to millions through Medicare. This creates an investment opportunity centered on the major pharmaceutical companies involved and the broader supply chain that will support the expected surge in demand.
Published: 8 November 2025
Explore BasketPharmaceutical Policy Shift Explained | Pricing Models
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published: 12 October 2025
Explore BasketWalgreens Restructuring Explained: Investment Shifts
Following its acquisition by Sycamore Partners, Walgreens has gone private and split into five companies. This theme explores the investment opportunities created by the newly independent healthcare and retail entities.
Published: 2 September 2025
Explore BasketWalgreens' Restructuring: A New Healthcare Landscape
Following its $10 billion acquisition by Sycamore Partners, Walgreens is going private and splitting into five separate companies. This major restructuring of a key industry player could create significant opportunities for competitors and specialized healthcare service providers to capture market share.
Published: 29 August 2025
Explore BasketMedicaid Politics
Discover companies whose fortunes are closely tied to government healthcare funding decisions. These carefully selected stocks represent businesses with significant exposure to Medicaid, now facing heightened legislative uncertainty after Senator Tillis's retirement.
Published: 30 June 2025
Explore BasketNeuro-Inclusive Employers
Explore companies that are tapping into neurodivergent talent as a strategic advantage. These forward-thinking organizations have established dedicated programs for recruiting and supporting employees with autism, ADHD, and other forms of neurodivergence, potentially driving innovation and long-term growth.
Published: 17 June 2025
Explore BasketEmployee Mental Health As A Benefit
Discover companies transforming workplace wellness through innovative mental health solutions. These carefully selected stocks represent businesses helping corporations attract and retain talent by offering digital therapy, virtual counseling, and wellness technologies as employee benefits.
Published: 17 June 2025
Explore BasketStagflation Standouts
This collection features stocks and assets carefully selected by professional analysts to potentially outperform during stagflation periods. These defensive investments have already shown strength while the broader market struggles, making them worth consideration for economic uncertainty ahead.
Published: 19 May 2025
Explore BasketWhy You’ll Want to Watch This Stock
Integrated care model
Vertical integration across pharmacies, PBM and insurance can create efficiencies and cross-selling opportunities, though benefits depend on successful integration and regulation.
Scale and reach
A large national footprint and broad customer base support stable prescription volumes, but competition from other chains and online players can pressure margins.
Services and tech
Investors may watch digital services, care management and cost controls as potential growth drivers, while remembering that execution and regulatory shifts add uncertainty.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
